Should prophylaxis for Pneumocystis jirovecii pneumonia be considered in patients with a CD4+ count higher than 200 cells/μl?

Orna Nitzan; Avi Peretz; Nina Pastukh; Margalit Lorber

doi:10.1097/QAD.0000000000000881

Should prophylaxis for Pneumocystis jirovecii pneumonia be considered in patients with a CD4⁺ count higher than 200 cells/μl?

Orna Nitzan, Avi Peretz, Nina Pastukh, Margalit Lorber

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2533-2534
Number of pages	2
Journal	AIDS
Volume	29
Issue number	18
DOIs	https://doi.org/10.1097/QAD.0000000000000881
State	Published - 2015
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0000000000000881

Cite this

@article{88e153cce8bf4830a45d27e2eb62433a,

title = "Should prophylaxis for Pneumocystis jirovecii pneumonia be considered in patients with a CD4+ count higher than 200 cells/μl?",

author = "Orna Nitzan and Avi Peretz and Nina Pastukh and Margalit Lorber",

year = "2015",

doi = "10.1097/QAD.0000000000000881",

language = "English",

volume = "29",

pages = "2533--2534",

journal = "AIDS",

issn = "0269-9370",